Human Metapneumovirus Diagnostics Market Report 2026

Human Metapneumovirus Diagnostics Market Overview

• Human Metapneumovirus Diagnostics market size has reached to $0.54 billion in 2025 • Expected to grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Surge In Respiratory Infections Fueling The Growth Of The Market Due To Increased Vulnerability And Need For Early Detection • Market Trend: Advancing Respiratory Diagnostics With Multiplex PCR For Timely Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Metapneumovirus Diagnostics Market?

Human metapneumovirus (hMPV) diagnostics refer to the methods and criteria used to detect and confirm infection with human metapneumovirus, a respiratory pathogen that can cause illnesses ranging from mild cold-like symptoms to severe respiratory tract infections, especially in children, the elderly, and immunocompromised individuals. The main product types in human metapneumovirus diagnostics are reagents and kits and instruments. Reagents and kits are essential laboratory products containing chemical substances and tools designed for performing specific diagnostic tests or experiments. The test types in this diagnostic are molecular diagnostics, immunodiagnostics, culture-based methods, and others, based on technologies such as PCR-based diagnostics, next-generation sequencing (NGS), immunofluorescence assays, lateral flow assays, microarray technology, and others used in the end uses, including hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, and others.

What Is The Human Metapneumovirus Diagnostics Market Growth Forecast?

The human metapneumovirus diagnostics market size is expected to see strong growth in the next few years. It will grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing demand for rapid respiratory diagnostics, expansion of multiplex and syndromic testing, growing investments in molecular diagnostic technologies, rising focus on early and accurate viral detection, increasing preparedness for seasonal respiratory outbreaks. Major trends in the forecast period include increasing adoption of molecular diagnostics for respiratory viruses, rising demand for rapid and point-of-care hmpv testing, growing emphasis on early detection in pediatric and geriatric care, expansion of multiplex respiratory pathogen testing panels, increasing integration of diagnostic results with clinical decision-making.

Global Human Metapneumovirus Diagnostics Market Segmentation

1) By Product Type: Reagents And Kits, Instruments 2) By Test Type: Molecular Diagnostics, Immunodiagnostics 3) By Technology: PCR-Based Diagnostics, Immunofluorescence Assays, Lateral Flow Assays 4) By End-Use: Hospitals And Clinics, Diagnostic And Reference Laboratories, Academic And Research Institutions, Other End Users Subsegments: 1) By Reagents And Kits: Sample Collection Kits, Nucleic Acid Extraction Kits, Viral Transport Media, Control Reagents 2) By Instruments: Thermal Cyclers, Automated Analyzers, Nucleic Acid Extractors, Fluorescence Readers

What Is The Driver Of The Human Metapneumovirus Diagnostics Market?

The rising prevalence of respiratory infections is expected to propel the growth in the human metapneumovirus diagnostics market going forward. Respiratory infections are illnesses caused by viruses, bacteria, or other pathogens that affect the respiratory system, including the sinuses, throat, airways, and lungs. The rising prevalence of respiratory infections can be attributed to respiratory infections, which expose individuals to harmful pollutants that irritate and weaken the respiratory tract, making it more vulnerable to infections. Human metapneumovirus diagnostics help identify hMPV as the cause of respiratory infections, enabling accurate treatment and better patient management. For instance, in January 2025, the UK Health Security Agency, a UK-based government agency, reported that during the 2023–2024 season, respiratory infection rates in England peaked at 8.0 per 100,000 in weeks 50 and 52 of 2023, rising further to 10.2 per 100,000 in week 4 of 2024, while acute respiratory infection (ARI) incidents in closed settings reached a total of 2,051, with the majority reported in care homes and hospitals. Therefore, the rising prevalence of respiratory infections is driving the growth of the human metapneumovirus diagnostics industry.

Key Players In The Global Human Metapneumovirus Diagnostics Market

Major companies operating in the human metapneumovirus diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Quest Diagnostics, Hologic Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, Qiagen NV, Diasorin, Luminex Corporation, bioMérieux, Seegene Inc., Cepheid, R-Biopharm AG, Certest Biotec, ZeptoMetrix, Xi'an Tianlong Science and Technology Co. Ltd, The Native Antigen Company, Hangzhou Testsea Biotechnology Co. Ltd., Attogene.

Global Human Metapneumovirus Diagnostics Market Trends and Insights

Major companies operating in the human metapneumovirus diagnostics market are focusing on developing innovative solutions, such as the respiratory polymerase chain reaction (PCR) diagnostic solution, to strengthen molecular diagnostic capabilities for detecting a broad range of respiratory pathogens. A respiratory polymerase chain reaction (PCR) diagnostic solution is a molecular testing method used to detect and identify respiratory pathogens by amplifying their genetic material with high sensitivity and specificity. For instance, in March 2023, Jiangsu BioPerfectus Technologies Co., Ltd., a China-based molecular diagnostic company, launched its respiratory pathogen multiplex real-time polymerase chain reaction (PCR) diagnostic kit. This solution is designed to simultaneously detect multiple respiratory pathogens with high accuracy and rapid turnaround time, enhancing diagnostic efficiency in clinical and point-of-care settings. Its comprehensive coverage and precise performance significantly support timely clinical decision-making, particularly in managing respiratory infections with overlapping symptoms.

What Are Latest Mergers And Acquisitions In The Human Metapneumovirus Diagnostics Market?

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Icosavax Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to strengthen its late-stage pipeline and expand its expertise in vaccines for high-burden respiratory conditions, particularly by advancing Icosavax’s lead investigational combination vaccine candidate, IVX-A12, which targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax Inc. is a US-based biotechnology company focused on developing vaccines, particularly combination vaccines targeting respiratory viruses such as respiratory syncytial virus (RSV) and hMPV.

Regional Outlook

North America was the largest region in the human metapneumovirus diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Metapneumovirus Diagnostics Market?

The human metapneumovirus diagnostics market consists of revenues earned by entities by providing services such as diagnostic testing services, clinical laboratory services, point-of-care testing services, home sample collection services, public health surveillance services, and contract research and testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus diagnostics market also includes sales of sample collection devices, diagnostic data management tools, test validation kits, and safety and waste disposal systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Metapneumovirus Diagnostics Market Report 2026?

The human metapneumovirus diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.